全文获取类型
收费全文 | 9813篇 |
免费 | 548篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 195篇 |
儿科学 | 284篇 |
妇产科学 | 232篇 |
基础医学 | 1803篇 |
口腔科学 | 167篇 |
临床医学 | 809篇 |
内科学 | 1792篇 |
皮肤病学 | 183篇 |
神经病学 | 919篇 |
特种医学 | 795篇 |
外科学 | 1421篇 |
综合类 | 85篇 |
一般理论 | 1篇 |
预防医学 | 404篇 |
眼科学 | 213篇 |
药学 | 586篇 |
中国医学 | 16篇 |
肿瘤学 | 491篇 |
出版年
2021年 | 106篇 |
2020年 | 74篇 |
2019年 | 79篇 |
2018年 | 140篇 |
2017年 | 138篇 |
2016年 | 147篇 |
2015年 | 166篇 |
2014年 | 231篇 |
2013年 | 356篇 |
2012年 | 386篇 |
2011年 | 395篇 |
2010年 | 308篇 |
2009年 | 265篇 |
2008年 | 380篇 |
2007年 | 387篇 |
2006年 | 406篇 |
2005年 | 406篇 |
2004年 | 362篇 |
2003年 | 353篇 |
2002年 | 361篇 |
2001年 | 180篇 |
2000年 | 180篇 |
1999年 | 153篇 |
1998年 | 176篇 |
1997年 | 132篇 |
1996年 | 128篇 |
1995年 | 124篇 |
1994年 | 95篇 |
1993年 | 92篇 |
1992年 | 121篇 |
1991年 | 128篇 |
1990年 | 110篇 |
1989年 | 87篇 |
1988年 | 81篇 |
1987年 | 85篇 |
1986年 | 80篇 |
1985年 | 67篇 |
1984年 | 64篇 |
1983年 | 66篇 |
1982年 | 58篇 |
1981年 | 62篇 |
1976年 | 63篇 |
1973年 | 67篇 |
1933年 | 69篇 |
1932年 | 62篇 |
1931年 | 58篇 |
1930年 | 76篇 |
1928年 | 60篇 |
1925年 | 65篇 |
1924年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Embolization for Hemoptysis in Chronic Thromboembolic Pulmonary Hypertension: Report of Two Cases and a Review of the Literature 总被引:1,自引:0,他引:1
Reesink HJ van Delden OM Kloek JJ Jansen HM Reekers JA Bresser P 《Cardiovascular and interventional radiology》2007,30(1):136-139
Hemoptysis is a known complication in patients with bronchial artery hypertrophy due to a variety of chronic pulmonary disorders.
Bronchial artery hypertrophy is observed in most patients with chronic thromboembolic pulmonary hypertension (CTEPH), but
surprisingly little is known about the incidence of hemoptysis in these patients. In this paper, we report on 2 patients with
CTEPH and recurrent severe hemoptysis, who were treated by bronchial artery embolization. One patient recovered and 1 patient
died as a consequence of the bleeding. A systematic review revealed 21 studies on the underlying pathology in 1,844 patients
with moderate to severe hemoptysis. CTEPH was reported to be the cause of bleeding in 0.1% (n = 2), pulmonary arterial hypertension without chronic thromboembolic disease in 0.2% (n = 4), and acute pulmonary embolism in 0.7% (n = 12) of the patients. In contrast to this, 5 patients (6%) in our own series of 79 CTEPH patients suffered from moderate
to severe hemoptysis requiring medical intervention. Severe hemoptysis appears to be an uncommon, but possibly underreported,
life-threatening complication in CTEPH patients. As most CTEPH patients require life-long anticoagulants a therapeutic dilemma
may ensue. Therefore, we propose that even mild hemoptysis in CTEPH patients warrants prompt evaluation, and treatment by
embolization should be offered as first choice in CTEPH patients. 相似文献
992.
Rennen HJ Laverman P van Eerd JE Oyen WJ Corstens FH Boerman OC 《Nuclear medicine and biology》2007,34(6):691-695
It was previously shown that the (99m)Tc-labeled hydrazinonicotinamide (HYNIC)-conjugated LTB4 antagonist MB81 visualized infectious foci in rabbits adequately and within a few hours after injection. Here, the bivalent HYNIC-conjugated LTB4 antagonist MB67 (analog of MB81) was fluorinated with (18)F via hydrazone formation and tested in vivo. METHODS: MB67 was [(18)F]-fluorinated via reaction of the [(18)F]-fluorinated intermediate p-[(18)F]-fluorobenzaldehyde ([(18)F]FB) and the HYNIC moiety of MB67 via hydrazone formation. For comparison, MB67 was also labeled with (99m)Tc. The biodistribution of (18)F- and (99m)Tc-labeled MB67 was investigated in rabbits with intramuscular infection. RESULTS: [(18)F]-MB67 was obtained at a maximum specific activity of 1200 GBq/mmol and proved to be stable in phosphate buffered saline (PBS) at 37 degrees C for at least 4 h. PET images obtained with [(18)F]-MB67 clearly delineated the abscess at 2 and 4 h pi. Counting of dissected tissues at 4 h pi revealed an abscess uptake of 0.073+/-0.005 %ID/g, as compared to 0.160+/-0.010 %ID/g for the (99m)Tc-labeled analog. Abscess-to-muscle ratios were 23+/-4 for [(18)F]-MB67 and 35+/-9 for [(99m)Tc]-MB67. CONCLUSION: The present study showed the feasibility of a new [(18)F]-labeling methodology and its application in the production of a new PET tracer for imaging of infection, [(18)F]-MB67. 相似文献
993.
Axer H Grässel D Brämer D Fitzek S Kaiser WA Witte OW Fitzek C 《Journal of magnetic resonance imaging : JMRI》2007,26(4):905-912
PURPOSE: To study the time course of diffusion imaging at the lesion site in brainstem infarcts. MATERIALS AND METHODS: Sequential MR scans were acquired from 24 patients with brainstem infarcts. Diffusion-weighted images (DWI), T(2)-weighted images (T(2)w), maps of apparent diffusion coefficient, and maps of fractional anisotropy were generated from each MR scan. A trend function was fitted to these measurements to model an objective, general time course of the studied parameters. RESULTS: Apparent diffusion coefficient (ADC) continuously decreased over time until a transition time around 45 hours; afterwards a continuous increase took place. After the 14th day ADC reached values similar to the ADC of the intact contralateral side (pseudonormalization) and then further increased. Fractional anisotropy (FA) decreased continuously over 3 to 6 months. CONCLUSION: Times of transition and pseudonormalization of ADC were longer than described for territorial hemispheric infarcts and describe the acute to subacute phase of brainstem ischemia. In contrast, the continuous decline of FA over 3 to 6 months indicates a chronic process of change of histological structures in brainstem ischemia, and may be regarded as an indicator of the chronic phase. 相似文献
994.
995.
996.
IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype 总被引:1,自引:0,他引:1
Otto Walter MD Manju Prasad MD Shaolei Lu MD PhD Robert M. Quinlan MD Kathryn L. Edmiston MD Ashraf Khan MD FRCPath 《Human pathology》2009,40(11):1528-1533
IMP3, an oncofetal protein, is a member of the insulin-like growth factor-II (IGF-II) mRNA-binding protein family. Its relevance as a novel biomarker in lung, pancreatic, renal, and cervical adenocarcinoma was recently revealed. However, its role in breast carcinogenesis and tumor progression is not yet established. Basal-like carcinoma was initially identified by gene expression profiling. It accounts for 15% to 30% of all breast cancers. These tumors express basal epithelial markers including cytokeratin 5 but lack expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), therefore, are often referred to as triple negative breast cancer. They have been found to be associated with a worse overall and disease-free survival. In this retrospective study, we examined the IMP3 expression in invasive ductal carcinoma of the breast and correlated its expression with morphological and biologic prognostic factors. The study group comprised 138 cases of invasive ductal carcinoma retrieved from the surgical pathologic files for a 10-year period from 1997 to 2006. Survival data and clinical stage were available on all 138 patients. Tumor characteristics including size, grade, lymphovascular invasion, necrosis, lymph node metastasis, estrogen receptor, progesterone receptor, and HER2 status were obtained from pathologic reports. Immunohistochemistry was performed on formalin-fixed paraffin-embedded tissue using mouse monoclonal antibody against IMP3 and CK5/6. Of the 138 breast cancer cases, IMP3 expression was seen in 45 (33%). Twenty-five of the IMP3+ cases were triple negative. We found significant correlation between IMP3 expression and higher grade (P = .001), necrosis (P< .0001) triple negative, and CK5/6 expression (P < .0001 for each). Cox multivariate analysis showed a hazard ratio of IMP3 expression at 3.14 (P = .05). IMP3 is a novel biomarker for triple negative (basal-like) invasive mammary carcinoma, and its expression is associated with a more aggressive phenotype and decreased overall survival. 相似文献
997.
Lúcia Inês Macedo-Souza Fernando Kok † Silvana Santos Luciana Licinio Karina Lezirovitz Natale Cavaçana Clarissa Bueno Simone Amorim ré Pessoa Zodja Graciani Áurea Ferreira Abdísio Prazeres Áurea Nogueira de Melo Paulo Alberto Otto Mayana Zatz 《Annals of human genetics》2009,73(3):382-387
SPOAN is an autosomal recessive neurodegenerative disorder which was recently characterized by our group in a large inbred Brazilian family with 25 affected individuals. This condition is clinically defined by: 1. congenital optic atrophy; 2. progressive spastic paraplegia with onset in infancy; and 3. progressive motor and sensory axonal neuropathy. Overall, we are now aware of 68 SPOAN patients (45 females and 23 males, with age ranging from 5 to 72 years), 44 of which are presented here for the first time. They were all born in the same geographic micro region. Those 68 patients belong to 43 sibships, 40 of which exhibit parental consanguinity. Sixty-one patients were fully clinically evaluated and 64 were included in the genetic investigation. All molecularly studied patients are homozygotes for D11S1889 at 11q13. This enabled us to reduce the critical region for the SPOAN gene from 4.8 to 2.3 Mb, with a maximum two point lod score of 33.2 (with marker D11S987) and of 27.0 (with marker D11S1889). Three genes located in this newly defined critical region were sequenced, but no pathogenic mutation was detected. The gene responsible for SPOAN remains elusive. 相似文献
998.
Sarah Jesse Petra Steinacker Stefan Lehnert Frank Gillardon Bastian Hengerer & Markus Otto 《CNS Neuroscience & Therapeutics》2009,15(2):157-182
The diagnosis of Parkinson disease (PD) is rendered on the basis of clinical parameters, whereby laboratory chemical tests or morphological imaging is only called upon to exclude other neurodegenerative diseases. The differentiation between PD and other diseases of the basal ganglia, especially the postsynaptic Parkinson syndromes multisystem atrophy (MSA) and progressive supranuclear palsy (PSP), is of decisive importance, on the one hand, for the response to an appropriate therapy, and on the other hand, for the respective prognosis of the disease. However, particularly at the onset of symptoms, it is difficult to precisely distinguish these diseases from each other, presenting with an akinetic-rigid syndrome. It is not yet possible to conduct a neurochemical differentiation of Parkinson syndromes. Therefore, a reliable biomarker is still to be found that might predict the development of Parkinson dementia. Since this situation is currently the subject of various different studies, the following synopsis is intended to provide a brief summary of the investigations addressing the field of the early neurochemical differential diagnosis of Parkinson syndromes and the early diagnosis of Parkinson dementia, from direct α-synuclein detection to proteomic approaches. In addition, an overview of the tested biomarkers will be given with regard to their possible introduction as a screening method. 相似文献
999.
1000.
Wagner P Olsson H Lidgren L Robertsson O Ranstam J 《European journal of cancer (Oxford, England : 1990)》2011,47(7):1061-1071